Harmony Biosciences Soars on Strong WAKIX Sales, Strategic Acquisitions

TL;DR

**HRMY is crushing it with WAKIX and smart M&A, making it a strong buy for growth in rare neurological diseases.**

AI Summary

Harmony Biosciences Holdings, Inc. (HRMY) reported robust financial performance for the nine months ended September 30, 2025, with net product revenue increasing by 21.7% to $624.677 million from $513.467 million in the prior year. Net income saw a significant jump of 41.8% to $136.201 million, up from $96.018 million in the same period of 2024. The company's cash and cash equivalents surged to $646.999 million as of September 30, 2025, from $453.001 million at December 31, 2024, indicating strong liquidity. Key business changes include the expansion into orexin science through a sublicense agreement for BP1.15205 in April 2024 and the acquisition of Epygenix Therapeutics, Inc. in April 2024, broadening its portfolio into rare epilepsy. Risks include dependence on WAKIX, potential competition, and the significant time and capital required for new product development and regulatory approval. The strategic outlook focuses on cultivating a differentiated neuroscience company by expanding its portfolio beyond histaminergic science into neurobehavioral and rare epilepsy diseases.

Why It Matters

This strong performance, driven by WAKIX and strategic acquisitions like Epygenix Therapeutics, signals Harmony Biosciences' successful execution in expanding its neuroscience portfolio. For investors, the 41.8% net income growth and increased cash reserves demonstrate financial health and potential for future growth, especially as they diversify beyond their lead product. Employees benefit from a growing company with expanded research and development initiatives, while customers could see new treatments for rare neurological diseases like Dravet Syndrome and Lennox-Gastaut Syndrome. In a competitive pharmaceutical landscape, Harmony's aggressive M&A and pipeline expansion position it as a more formidable player against larger biotech firms.

Risk Assessment

Risk Level: medium — The company's risk level is medium due to its heavy reliance on a single commercialized product, WAKIX, as stated in the filing: "The Company currently has one commercialized product, WAKIX." While expanding, the success of new product candidates like BP1.15205 and clemizole hydrochloride is uncertain and subject to significant regulatory and clinical trial risks, requiring substantial time and capital.

Analyst Insight

Investors should consider holding or initiating a position in HRMY, given its strong revenue and net income growth, robust cash position of $646.999 million, and strategic expansion into new therapeutic areas. Monitor the progress of its pipeline assets, particularly BP1.15205 and clemizole hydrochloride, as successful development could further de-risk the company and drive long-term value.

Financial Highlights

debt To Equity

0.45

revenue

$624.677M

operating Margin

27.2%

total Assets

$1.208B

total Debt

$172.506M

net Income

$136.201M

eps

$0.87

gross Margin

79.2%

cash Position

$646.999M

revenue Growth

+21.7%

Revenue Breakdown

Key Numbers

• $624.677M — Net product revenue (Increased by 21.7% for the nine months ended September 30, 2025, compared to $513.467 million in 2024.)
• $136.201M — Net income (Increased by 41.8% for the nine months ended September 30, 2025, compared to $96.018 million in 2024.)
• $646.999M — Cash and cash equivalents (As of September 30, 2025, a significant increase from $453.001 million at December 31, 2024.)
• $179.805M — Gross profit (Q3 2025) (Increased from $143.260 million in Q3 2024, reflecting strong product sales.)
• $54.962M — Research and development expenses (Q3 2025) (Increased from $25.387 million in Q3 2024, indicating significant investment in pipeline expansion.)
• $138.417M — Retained earnings (As of September 30, 2025, a substantial increase from $2.216 million at December 31, 2024.)
• $0.87 — Diluted EPS (Q3 2025) (Increased from $0.79 in Q3 2024, demonstrating improved profitability per share.)
• 57,596,358 — Shares outstanding (As of October 31, 2025, reflecting a slight increase from 57,144,887 at December 31, 2024.)

Key Players & Entities

• Harmony Biosciences Holdings, Inc. (company) — registrant
• WAKIX (company) — lead product
• Bioprojet Socit Civile de Recherche (company) — licensor of pitolisant and BP1.15205
• Zynerba Pharmaceuticals, Inc. (company) — acquired company in October 2023
• Epygenix Therapeutics, Inc. (company) — acquired company in April 2024
• Teijin Pharma (company) — innovator of BP1.15205
• FDA (regulator) — approved WAKIX in 2019, 2020, and 2024
• BP1.15205 (company) — preclinical orexin 2 receptor agonist
• clemizole hydrochloride (company) — licensed for Dravet Syndrome and Lennox-Gastaut Syndrome
• SEC (regulator) — governs financial reporting

FAQ

Risk Factors

• Dependence on WAKIX [high — operational]: The company's primary revenue driver is WAKIX. Any disruption in its sales, market acceptance, or competitive landscape could significantly impact financial performance. The report highlights the need for continued growth beyond this single product.
• Potential Competition [medium — market]: The pharmaceutical market is highly competitive. New entrants or existing players developing similar therapies could erode market share and impact pricing power. The company's expansion into new therapeutic areas also exposes it to established competitors in those fields.
• Product Development Costs [medium — financial]: Developing new pharmaceutical products requires substantial and sustained capital investment. The report notes the significant time and capital needed for research, development, and regulatory approval, posing a financial risk if pipeline candidates do not succeed.
• Regulatory Approval Process [high — regulatory]: Gaining regulatory approval for new drugs is a lengthy and uncertain process. Delays or rejections from regulatory bodies like the FDA can significantly impact timelines and the commercial viability of new products, as seen in the general risks of drug development.
• Integration of Acquisitions [medium — operational]: The acquisition of Epygenix Therapeutics, Inc. and the sublicense agreement for BP1.15205 represent strategic expansions. However, integrating these new assets and realizing their full potential involves operational risks, including synergy realization and management bandwidth.

Industry Context

Harmony Biosciences operates in the highly competitive biopharmaceutical industry, focusing on rare neurological diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Key trends include the increasing demand for specialized therapies for rare conditions and the strategic importance of pipeline diversification through internal development and acquisitions.

Regulatory Implications

The company faces ongoing regulatory scrutiny inherent in the pharmaceutical sector. Successful navigation of the FDA approval process for new drug candidates is critical. Changes in regulatory policies or increased compliance costs could impact development timelines and market access for its products.

What Investors Should Do

1. Monitor R&D pipeline progress, particularly for BP1.15205 and rare epilepsy treatments, as these represent future growth drivers beyond WAKIX.
2. Assess the competitive landscape for narcolepsy and potential new indications, as increased competition could pressure WAKIX's market share.
3. Evaluate the company's ability to successfully integrate Epygenix Therapeutics and realize synergies, which is key to its rare epilepsy strategy.
4. Observe the trend in operating expenses, especially R&D, to ensure investments are translating into pipeline advancements without excessive cost overruns.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported significant revenue growth of 21.7% and net income increase of 41.8%, demonstrating strong operational performance and market traction.
• 2025-09-30: Cash and cash equivalents as of September 30, 2025 — Reached $646.999 million, a substantial increase from $453.001 million at December 31, 2024, indicating robust liquidity and financial flexibility.
• 2024-04-01: Sublicense agreement for BP1.15205 — Expanded the company's focus into orexin science, diversifying its pipeline and therapeutic areas.
• 2024-04-01: Acquisition of Epygenix Therapeutics, Inc. — Broadened the company's portfolio into rare epilepsy, further diversifying its therapeutic focus and potential revenue streams.
• 2025-10-31: Shares outstanding as of October 31, 2025 — Totaled 57,596,358, a slight increase from December 31, 2024, indicating minimal dilution from stock issuances.

Glossary

Net product revenue

The total revenue generated from the sale of the company's pharmaceutical products after accounting for returns, allowances, and discounts. (This is the primary top-line metric for the company, directly reflecting the commercial success of its products like WAKIX.)

Retained earnings

The cumulative amount of net income that a company has kept over time, rather than distributing to shareholders as dividends. (A significant increase in retained earnings from $2.216 million to $138.417 million indicates strong profitability and reinvestment of earnings.)

Intangible assets, net

Assets that lack physical substance but have value, such as patents, trademarks, and goodwill, net of accumulated amortization. (The decrease from $113.263 million to $95.380 million suggests amortization of existing intangible assets, potentially related to product lifecycles or acquisitions.)

Deferred tax asset

A future tax benefit that a company can use to reduce its taxable income in the future, often arising from temporary differences between accounting and tax rules. (The decrease from $190.398 million to $157.075 million may reflect the utilization of these tax benefits or changes in future taxable income expectations.)

Diluted EPS

Earnings per share calculated by dividing net income by the total number of diluted shares outstanding, including potential shares from stock options and convertible securities. (The increase in Diluted EPS from $0.79 in Q3 2024 to $0.87 in Q3 2025 shows improved profitability on a per-share basis.)

Orexin science

A field of study focused on orexin neuropeptides, which play a role in regulating wakefulness, arousal, and appetite. (Harmony Biosciences is expanding into this area with its sublicense agreement for BP1.15205, indicating a strategic move into new therapeutic targets.)

Year-Over-Year Comparison

Harmony Biosciences has demonstrated significant year-over-year improvement. Net product revenue for the nine months ended September 30, 2025, increased by 21.7% to $624.677 million, while net income surged by 41.8% to $136.201 million. This growth is accompanied by a substantial increase in cash and cash equivalents to $646.999 million. Operating expenses, particularly R&D, have increased, reflecting strategic investments in pipeline expansion, which investors should monitor for future returns. New risks related to integration of recent acquisitions and diversification into new therapeutic areas are now more prominent.

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 value per share HRMY The Nasdaq Sto

Filing Documents

• hrmy-20250930x10q.htm (10-Q) — 1792KB
• hrmy-20250930xex31d1.htm (EX-31.1) — 16KB
• hrmy-20250930xex31d2.htm (EX-31.2) — 16KB
• hrmy-20250930xex32d1.htm (EX-32.1) — 10KB
• hrmy-20250930xex32d2.htm (EX-32.2) — 9KB
• 0001104659-25-105962.txt ( ) — 9065KB
• hrmy-20250930.xsd (EX-101.SCH) — 70KB
• hrmy-20250930_cal.xml (EX-101.CAL) — 81KB
• hrmy-20250930_def.xml (EX-101.DEF) — 215KB
• hrmy-20250930_lab.xml (EX-101.LAB) — 574KB
• hrmy-20250930_pre.xml (EX-101.PRE) — 402KB
• hrmy-20250930x10q_htm.xml (XML) — 1702KB

Financial Information

Part I. Financial Information 3

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets (Unaudited) 3 Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) 4 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) 5 Condensed Consolidated Statements of Cash Flows (Unaudited) 6 Notes to Condensed Consolidated Financial Statements (Unaudited) 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 42

Controls and Procedures

Item 4. Controls and Procedures 43

Other Information

Part II. Other Information 44

Legal Proceedings

Item 1. Legal Proceedings 44

Risk Factors

Item 1A. Risk Factors 44

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44

Defaults upon Senior Securities

Item 3. Defaults upon Senior Securities 44

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 44

Other Information

Item 5. Other Information 44

Exhibits

Item 6. Exhibits 45

Signatures

Signatures 46 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) September 30, December 31, 2025 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 646,999 $ 453,001 Investments, short-term 25,582 14,185 Trade receivables, net 100,651 83,033 Inventory, net 6,882 7,198 Prepaid expenses 23,308 13,714 Other current assets 35,378 8,121 Total current assets 838,800 579,252 NONCURRENT ASSETS: Property and equipment, net 1,440 1,257 Investments, long-term 105,831 108,874 Intangible assets, net 95,380 113,263 Deferred tax asset 157,075 190,398 Other noncurrent assets 9,692 6,156 Total noncurrent assets 369,418 419,948 TOTAL ASSETS $ 1,208,218 $ 999,200 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Trade payables $ 26,341 $ 13,744 Accrued compensation 14,935 18,776 Accrued expenses 161,302 120,640 Current portion of long-term debt 20,000 16,250 Other current liabilities 825 5,672 Total current liabilities 223,403 175,082 NONCURRENT LIABILITIES: Long-term debt, net 148,506 163,016 Other noncurrent liabilities 1,186 1,947 Total noncurrent liabilities 149,692 164,963 TOTAL LIABILITIES 373,095 340,045 COMMITMENTS AND CONTINGENCIES (Note 13) STOCKHOLDERS' EQUITY: Common stock—$ 0.00001 par value; 500,000,000 shares authorized at September 30, 2025 and December 31, 2024, respectively; 57,596,358 and 57,144,887 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 1 1 Additional paid in capital 696,348 656,872 Accumulated other comprehensive income 357 66 Retained earnings 138,417 2,216 TOTAL STOCKHOLDERS' EQUITY 835,123 659,155 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 1,208,218 $ 999,200 The accompanying notes are an integral part of the un